The advent of gene targeting technology in mouse embryonic stem (ES) cells has made it possible to introduce specific mutations into the murine germline. Over the past several years we have used this technology to mutate the murine homologues of a series of human genes implicated in tumor development, specifically the tumor suppressor genes Rb, p53, Nf1 and Nf2. These mutant animals have been useful as models for certain human familial cancer syndromes caused by the inheritance of a single mutant allele of a given tumor suppressor gene, as a means to address the role for these genes in normal development, and as a source of primary cells and cell lines with which to examine tumor suppressor gene function in vitro. Recently, we have also developed a novel mouse strain carrying a targeted mutation in the K-ras proto-oncogene, which causes predisposition to tumors of the lung and other sites. This lecture will summarize our progress in the study of these mutant mouse strains, with a particular emphasis on their value as animals models of human tumor development.
In humans, inheritance of a defective allele of a tumor suppressor gene strongly predisposes to tumor development. Similarly, mice heterozygous for a mutation in Rb, p53, Nfl or Nf2 are cancer prone. Importantly, however, although these animals exhibit increased cancer risk, the tumor types that they develop typically differ from those seen in the cognate human familial cancer syndrome. For example, while Rb + / -humans develop retinoblastoma, Rb + / -mice never develop this tumors; rather, these mice succumb to tumors of the intermediate lobe of the pituitary. Likewise, Nfl + / -mice do not develop the common symptoms of neurofibromatosis type 1, and instead develop myeloid Therefore, we have continued to study tumor phenotypes without consideration of the related human condition. For example, we are currently characterizing the effects of combined mutations in several tumor suppressor genes (e.g., Nfl/p53 and Nf2/ p53). These double mutant animals develop tumors (largely sarcomas) much more rapidly than the relevant single mutants, indicating a degree of cooperativity in the tumorigenic effects of these mutations. Moreover, because of the short latency of tumor development in these strains, they should be very useful for therapeutic evaluation. 
